Received Mar 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | UNK | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | UNK | — |
received first dose of Bexsero at 7 months and the second dose after a year; This non-serious case was reported by a consumer via call center representative and described the occurrence of inappropriate age at vaccine administration in a 7-month-old female patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included Men B NVS (Bexsero) for prophylaxis. On an unknown date, the patient received the 2nd dose of Bexsero and the 1st dose of Bexsero. On an unknown date, an unknown time after receiving Bexsero and Bexsero, the patient experienced inappropriate age at vaccine administration (Verbatim: received first dose of Bexsero at 7 months and the second dose after a year). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 05-MAR-2025 The patient was 3 years and 10 months of age. The reporter had a child who received first dose of Bexsero at 7 months and the second dose after a year, which led to inappropriate age at vaccine administration. The reporter asked that was this safe or she should get another dose.